Difference between revisions of "Sunitinib"
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
{{Reflist|1}} | {{Reflist|1}} | ||
[[Category: Clinical]] | [[Category:Clinical]] | ||
[[Category:Drugs]] | |||
Revision as of 14:49, 30 May 2016
Sunitinib (marketed with the brand name Sutent) is a tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC).
In RCC acts on:[1]
- VEGF.
- PDGFbeta.